Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)’s Late-Breaking Presentation, Conference Call and Research Publications


Dallas, Texas 12/03/2014 (FINANCIALSTRENDS) – Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) recently announced that its abstracts highlighting results from Phase III VALOR trial are accepted in a late-breaking session at the 56th Annual Meeting of ASH (American Society of Hematology). The meeting will take place in San Francisco, California from December 6-9, 2014.

VALOR trial studied the effect of vosaroxin and cytarabine treatment in patients with relapsed or refractory AML (acute myeloid leukemia). More recently, the company announced to host a conference call following the presentation at the ASH Annual Meeting. The call and slide webcast are scheduled for December 9, 2014, at 10:30 a.m. PT.

Sunesis will discuss the results of VALOR trial as well as that of Phase I/II vosaroxin and decitabine study in newly diagnosed older patients with AML and high-risk myelodysplastic syndrome.

Late-Breaking Presentation

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)’s vosaroxin is an anti-cancer derivative belonging to quinolone compounds, which are not previously used as cancer therapy. Daniel Swisher, CEO of Sunesis, said that outcomes are unacceptably poor in relapsed refractory AML and yet drug therapy has changed little over the past four decades. The results of VALOR trial could demonstrate clinically important advancement in the treatment of this condition.

The oral presentation is scheduled on December 9, 2014, at 08:45 a.m. and will highlight improved survival in patients with first relapsed or refractory AML.

Research Publications

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced the peer-reviewed publication of REVEAL-1 results in the British Journal of Haematology. The Phase II trial assessed vosaroxin mono-therapy in previously untreated, poor-risk elderly patients with AML, who are unlikely to benefit from standard chemotherapy.

The company also announced publication of Phase Ib/II study results assessing the impact of combination therapy of vosaroxin and cytarabine in patients with relapsed or refractory AML. The results are published in the Ahead of Print issue of Haematologica.